Vanda Pharmaceuticals, Inc. (VNDA)

[surf1944]

4:01PM Vanda Pharma announces U.S. patent allowance for a long-acting injectable formulation of fanapt in the U.S. (VNDA) 10.29 -0.08 : Co announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.